{"description":"Documents matching 'remote patient monitoring'","count":1259,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=remote+patient+monitoring&format=json&page=2","results":[{"title":"Advisory Committee; Digital Health Advisory Committee; Addition to List of Standing Committees","type":"Rule","abstract":"The Food and Drug Administration (FDA or Agency) is amending the standing advisory committees regulations to add the establishment of the Digital Health Advisory Committee (the Committee) to the list of standing advisory committees.","document_number":"2024-03618","html_url":"https://www.federalregister.gov/documents/2024/02/22/2024-03618/advisory-committee-digital-health-advisory-committee-addition-to-list-of-standing-committees","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-02-22/pdf/2024-03618.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-03618.pdf?1708523125","publication_date":"2024-02-22","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"digital health, such as artificial intelligence/machine learning, augmented reality, virtual reality, digital therapeutics, wearables, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, software development, user experience, real-world data, real-world evidence, <span class=\"match\">patient</span>-generated health data, interoperability, personalized medicine/genetics, decentralized clinical trials, cybersecurity, and implementation in clinical practice of and <span class=\"match\">patient</span> experience with digital health, as well as other relevant areas. Members will be invited to serve for overlapping terms of up to 4 years"},{"title":"Advisory Committee; Digital Health Committee; Establishment","type":"Notice","abstract":"Under the Federal Advisory Committee Act, the Food and Drug Administration (FDA or Agency) is announcing the establishment of the Digital Health Advisory Committee. The Commissioner of Food and Drugs (Commissioner) has determined that it is in the public interest to establish such a committee. Duration of this committee is 2 years from the date the Charter is filed, unless the Commissioner formally determines that renewal is in the public interest.","document_number":"2023-22566","html_url":"https://www.federalregister.gov/documents/2023/10/12/2023-22566/advisory-committee-digital-health-committee-establishment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-12/pdf/2023-22566.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-22566.pdf?1697028379","publication_date":"2023-10-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"algorithms \n • Digital therapeutics \n • AI/ML \n • Input on regulation of AI/ML-enabled devices \n • Real-world data and real-world evidence \n • <span class=\"match\">Patient</span>-generated health data \n • Postmarket <span class=\"match\">monitoring</span> considerations for a total product lifecycle approach to DHTs \n • Interoperability \n • Personalized medicine/genetics \n • Wearables, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, and internet of things \n • Postmarket <span class=\"match\">monitoring</span> of DHTs \n • Technologies to enable decentralized clinical trials \n • Cybersecurity best practices in software development for cloud-based software"},{"title":"Request for Nominations for Voting Members for the Digital Health Advisory Committee","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is requesting nominations for voting members, excluding consumer and industry representatives, to serve on the Digital Health Advisory Committee (the Committee) in the Center for Devices and Radiological Health. Nominations will be accepted for current vacancies effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.","document_number":"2023-22569","html_url":"https://www.federalregister.gov/documents/2023/10/12/2023-22569/request-for-nominations-for-voting-members-for-the-digital-health-advisory-committee","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-12/pdf/2023-22569.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-22569.pdf?1697028384","publication_date":"2023-10-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"digital health, such as artificial intelligence/machine learning, augmented reality, virtual reality, digital therapeutics, wearables, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, software development, user experience, real-world data, real-world evidence, <span class=\"match\">patient</span>-generated health data, interoperability, personalized medicine/genetics, decentralized clinical trials, cybersecurity, and implementation in clinical practice of and <span class=\"match\">patient</span> experience with digital health, as well as other relevant areas. Members will be invited to serve for overlapping terms of up to 4 years"},{"title":"Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies","type":"Proposed Rule","abstract":"This proposed rule would set forth routine updates to the Medicare home health payment rates in accordance with existing statutory and regulatory requirements. In addition, this proposed rule discusses the behavior adjustment and proposes a temporary behavior adjustment and proposes to recalibrate the case-mix weights and update the functional impairment levels; comorbidity subgroups; and low- utilization payment adjustment (LUPA) thresholds for CY 2027. Additionally, this proposed rule discusses the provision of home health palliative care services and includes a request for information (RFI) on a home health specific wage index. This rule would also propose changes to the Home Health Quality Reporting Program (HH QRP) and summarizes potential initiatives to improve alignment between the HH QRP and expanded Home Health Value Based Purchasing (HHVBP) Model. Lastly, the rule would--clarify the application of the DMEPOS face-to- face encounter requirements for the replacement of DMEPOS items; make changes to the provider and supplier enrollment requirements; make changes regarding DME benefit expansion for infusion pumps and drugs; and discuss collection of information requirement changes regarding the DMEPOS Competitive Bidding Program (CBP) country of origin.","document_number":"2026-13602","html_url":"https://www.federalregister.gov/documents/2026/07/06/2026-13602/calendar-year-2027-home-health-prospective-payment-system-hh-pps-rate-update-requirements-for-the-hh","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13602.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13602.pdf?1782936912","publication_date":"2026-07-06","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"physiologic data digitally stored and/or transmitted by the <span class=\"match\">patient</span> to the HHA, that is, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> (G0322). We capture the usage and length of <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> using the start date of the <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> and the number of days of <span class=\"match\">monitoring</span> indicated on the claim. We also looked at the disciplines most often providing <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>. We examined the utilization of telecommunications technology devices during a home health period and <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> by looking at home health claims that included the"},{"title":"Request for Nominations of Individuals and Industry Organizations for the Digital Health Advisory Committee","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is requesting nominations for temporary nonvoting industry representatives to be included in a pool of individuals to serve on the Digital Health Advisory Committee. FDA is also requesting that industry organizations interested in participating in the selection of a pool of nonvoting industry representatives to serve as temporary nonvoting members on the Digital Health Advisory Committee (the Committee) in the Center for Devices and Radiological Health notify FDA in writing. Nominees recommended to serve as a temporary nonvoting industry representative may either be self-nominated or nominated by an industry organization. This position may be filled by representatives of different medical device areas based on areas of expertise relevant to the topics being considered by the Committee. Nominations will be accepted for current vacancies effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore encourages nominations of appropriately qualified candidates from these groups.","document_number":"2023-22568","html_url":"https://www.federalregister.gov/documents/2023/10/12/2023-22568/request-for-nominations-of-individuals-and-industry-organizations-for-the-digital-health-advisory","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-12/pdf/2023-22568.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-22568.pdf?1697028383","publication_date":"2023-10-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"subject to FDA regulation. Topics relating to DHTs, such as artificial intelligence/machine learning, augmented reality, virtual reality, digital therapeutics, wearables, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, and software, may be considered by the Committee. The Committee advises the Commissioner on issues related to DHTs, including, for example, real-world data, real-world evidence, <span class=\"match\">patient</span>-generated health data, interoperability, personalized medicine/genetics, decentralized clinical trials, use of DHTs in clinical trials for medical products, cybersecurity"},{"title":"Request for Nominations of Individuals and Consumer Organizations for the Digital Health Advisory Committee","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is requesting nominations for a voting consumer representative to serve on the Digital Health Advisory Committee. FDA is also requesting that any consumer organizations interested in participating in the selection of a voting consumer representative to serve on the Digital Health Advisory Committee notify FDA in writing. Nominees recommended to serve as a voting consumer representative may either be self-nominated or may be nominated by a consumer organization. Nominations will be accepted for the current vacancy effective with this notice. FDA seeks to include the views of members of all gender groups, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore encourages nominations of appropriately qualified candidates from these groups.","document_number":"2023-22567","html_url":"https://www.federalregister.gov/documents/2023/10/12/2023-22567/request-for-nominations-of-individuals-and-consumer-organizations-for-the-digital-health-advisory","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-12/pdf/2023-22567.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-22567.pdf?1697028382","publication_date":"2023-10-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"subject to FDA regulation. Topics relating to DHTs, such as artificial intelligence/machine learning, augmented reality, virtual reality, digital therapeutics, wearables, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, and software, may be considered by the Committee. The Committee advises the Commissioner on issues related to DHTs, including, for example, real-world data, real-world evidence, <span class=\"match\">patient</span>-generated health data, \n \n interoperability, personalized medicine/genetics, decentralized clinical trials, use of DHTs in clinical trials for medical products, cybersecurity"},{"title":"Further Extension of the Flexibility in Evaluating “Close Proximity of Time” To Evaluate Ongoing Changes in Healthcare","type":"Rule","abstract":"We are extending the flexibility in the \"close proximity of time\" standard, as defined in two prior temporary final rules (TFR), through May 11, 2029. We issued a TFR providing the \"close proximity of time\" flexibility on July 23, 2021, because the COVID-19 national public health emergency (PHE) caused many individuals to experience barriers that prevented them from timely accessing in-person healthcare. On September 29, 2023, we extended the flexibility to evaluate evolving healthcare practices and consumption in a post-PHE environment. We determined that we need additional time to fully evaluate still-evolving healthcare practices after the PHE. We are therefore issuing this TFR to extend the \"close proximity of time\" flexibility until May 11, 2029, so we can continue to evaluate changes in healthcare practices and determine the proper \"close proximity of time\" standard for the musculoskeletal disorders listings.","document_number":"2025-01283","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01283/further-extension-of-the-flexibility-in-evaluating-close-proximity-of-time-to-evaluate-ongoing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01283.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01283.pdf?1737035141","publication_date":"2025-01-17","agencies":[{"raw_name":"Social Security Administration","name":"Social Security Administration","id":470,"url":"https://www.federalregister.gov/agencies/social-security-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/470","parent_id":null,"slug":"social-security-administration"}],"excerpts":"through telemedicine, and found that while the <span class=\"match\">patient</span> could perform many tests, there are inherent limitations to testing in this manner. For example, the authors recommend using another person to hold the camera during gait examination to get a better view of the <span class=\"match\">patient's</span> gait mechanics, which is not always possible.\n 42 \n \n Further, the VHA has found that although <span class=\"match\">patients</span> appreciate telehealth, many are unable to complete exams that require precise measurements, such as range of motion or reflexes.\n 43 \n \n While it appears that since the end of the"},{"title":"Enforcement Policy for Non-Invasive Remote Monitoring Devices Used To Support Patient Monitoring; Guidance for Industry and Food and Drug Administration Staff; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled \"Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring.\" The enforcement policy described in this guidance applies to modified devices where the original device was a legally marketed, non-invasive remote monitoring device listed in the guidance that measures or detects common physiological parameters and that is used to support patient monitoring. The guidance is intended to describe the enforcement policy for limited modifications to the indications, functionality, or hardware or software of device types in the scope of the guidance without prior submission of a 510(k) where such submission would be required.","document_number":"2023-23110","html_url":"https://www.federalregister.gov/documents/2023/10/19/2023-23110/enforcement-policy-for-non-invasive-remote-monitoring-devices-used-to-support-patient-monitoring","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-10-19/pdf/2023-23110.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-23110.pdf?1697633241","publication_date":"2023-10-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"is announcing the availability of a final guidance entitled “Enforcement Policy for Non-Invasive <span class=\"match\">Remote</span> <span class=\"match\">Monitoring</span> Devices Used to Support <span class=\"match\">Patient</span> <span class=\"match\">Monitoring</span>.” The enforcement policy described in this guidance applies to modified devices where the original device was a legally marketed, non-invasive <span class=\"match\">remote</span> <span class=\"match\">monitoring</span> device listed in the guidance that measures or detects common physiological parameters and that is used to support <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>. The guidance is intended to describe the enforcement policy for limited modifications to the indications"},{"title":"Medicare Program; Calendar Year (CY) 2025 Home Health Prospective Payment System (HH PPS) Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin (IVIG) Items and Services Rate Update; and Other Medicare Policies","type":"Proposed Rule","abstract":"This proposed rule would set forth routine updates to the Medicare home health payment rates; the payment rate for the disposable negative pressure wound therapy (dNPWT) devices; and the intravenous immune globulin (IVIG) items and services payment rate for CY 2025 in accordance with existing statutory and regulatory requirements. In addition, it proposes changes to the Home Health Quality Reporting Program (HH QRP) requirements and provides an update on potential approaches for integrating health equity in the Expanded Health Value Based Purchasing (HHVBP) Model. It also proposes a new standard for acceptance to service policy in the HH conditions of participation (CoPs) and includes requests for information (RFIs) soliciting input on permitting rehabilitative therapists to conduct the initial and comprehensive assessment and the factors that may influence the patient referral and intake processes. Lastly, it proposes updates to provider and supplier enrollment requirements and changes to the long-term care reporting requirements for acute respiratory illnesses.","document_number":"2024-14254","html_url":"https://www.federalregister.gov/documents/2024/07/03/2024-14254/medicare-program-calendar-year-cy-2025-home-health-prospective-payment-system-hh-pps-rate-update-hh","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-03/pdf/2024-14254.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-14254.pdf?1719432920","publication_date":"2024-07-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"data digitally stored and/or transmitted by the <span class=\"match\">patient</span> to the home health agency, that is, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> (G0322). We capture the usage and length of <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> using the start date of the <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> and the number of days of <span class=\"match\">monitoring</span> indicated on the claim. We also looked at the disciplines most often providing <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>. We examined the utilization of telecommunications technology device during a home health period and <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> by looking at home health claims that included"},{"title":"Expansion of Validated End User Authorization: Data Center Validated End User Authorization","type":"Rule","abstract":"In this rule, the Department of Commerce, Bureau of Industry and Security (BIS), amends the Export Administration Regulations (EAR) to expand the Validated End User Authorization (VEU) program to include VEU Authorization for data centers located in specified destinations (\"Data Center VEU\" or \"Data Center VEU Authorization\"). This expansion of the VEU program to include Data Center VEU is intended to facilitate quick and reliable export or reexport of items on the Commerce Control List necessary for a data center, including advanced computing items, to preapproved trusted end users. Data Center VEU adopts much of the framework of the existing VEU program, with additional requirements. This expansion of eligibility is intended to update the VEU program to recognize the advancement and benefits of artificial intelligence. As under the original VEU Authorization Program, the U.S. government will rigorously review Data Center VEU candidates' applications subject to detailed and verifiable criteria.","document_number":"2024-22587","html_url":"https://www.federalregister.gov/documents/2024/10/02/2024-22587/expansion-of-validated-end-user-authorization-data-center-validated-end-user-authorization","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-02/pdf/2024-22587.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-22587.pdf?1727700348","publication_date":"2024-10-02","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"Bureau of Industry and Security","name":"Industry and Security Bureau","id":241,"url":"https://www.federalregister.gov/agencies/industry-and-security-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/241","parent_id":54,"slug":"industry-and-security-bureau"}],"excerpts":"complex problems such as climate change. For example, AI-enabled virtual learning systems can be tailored to a student's needs to bridge the education gap in regions that lack resources or qualified teachers. AI can also improve access to healthcare by facilitating <span class=\"match\">remote</span>-<span class=\"match\">patient</span> <span class=\"match\">monitoring</span>. \n At the same time, AI is revolutionizing the military and intelligence capabilities of adversaries. Advanced AI models, trained on advanced computing integrated circuits, have the potential to diffuse dangerous capabilities by lowering the barrier to develop cyberweapons"},{"title":"Continuity of Care via Telemedicine for Veterans Affairs Patients","type":"Rule","abstract":"This final rule authorizes Department of Veterans Affairs (VA) practitioners acting within the scope of their VA employment to prescribe controlled substances via telemedicine to a VA patient with whom they have not conducted an in-person medical evaluation. VA practitioners are permitted to prescribe controlled substances to VA patients if another VA practitioner has, at any time, previously conducted an in-person medical evaluation of the VA patient, subject to certain conditions.","document_number":"2025-01044","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01044/continuity-of-care-via-telemedicine-for-veterans-affairs-patients","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01044.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01044.pdf?1736948756","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"(transfers to the <span class=\"match\">patient</span>) is $146,644 ($2.22 × 66,056). Subtracting the VA reimbursement amount from the total cost savings, DEA estimates a total <span class=\"match\">patient</span> net cost savings of $2,393,870 ($2,540,514 − $146,644) per year. Table 10 summarizes this calculation. \n \n Table 10—Total Cost/Transfer Savings \n \n   \n \n Total cost\n savings \n ($) \n \n \n VA\n reimbursement \n ($) \n \n \n <span class=\"match\">Patient</span> net\n cost savings \n ($) \n \n \n \n <span class=\"match\">Patient</span> cost savings (per visit) \n 38.46 \n 2.22 \n N/A \n \n \n <span class=\"match\">Patient</span> cost savings \n 2,540,514 \n 146,644 \n 2,393,870 \n \n \n e. <span class=\"match\">Patient</span> Benefit: Increased"},{"title":"Special Registrations for Telemedicine and Limited State Telemedicine Registrations","type":"Proposed Rule","abstract":"The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the \"Ryan Haight Act\") generally requires an in-person medical evaluation prior to the issuance of a prescription of controlled substances but provides an exception to this in-person medical evaluation requirement where the practitioner is engaged in the \"practice of telemedicine\" within the meaning of the Ryan Haight Act. These proposed regulatory changes would establish a Special Registration framework and authorize three types of Special Registration. This proposed rulemaking also provides for heightened prescription, recordkeeping, and reporting requirements. DEA believes such changes are necessary to effectively expand patient access to controlled substance medications via telemedicine while mitigating the risks of diversion associated with such expansion. A summary of this rule may be found at https://www.regulations.gov/docket/DEA-2023-0029.","document_number":"2025-01099","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01099/special-registrations-for-telemedicine-and-limited-state-telemedicine-registrations","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01099.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01099.pdf?1736948758","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"the <span class=\"match\">patient</span> with other forms of documentation, and would require the \n clinician special registrant \n to maintain a record of how they verified the <span class=\"match\">patient's</span> identity and what documents were used to verify the <span class=\"match\">patient's</span> identity. For example, a \n clinician special registrant \n (or their delegated employee or contractor under their direct supervision) might verify <span class=\"match\">patient</span> identity by observing a <span class=\"match\">patient's</span> pay stub and/or a bill with the <span class=\"match\">patient's</span> home address, a letter provided by a shelter employee if the <span class=\"match\">patient</span> is unhoused, or a <span class=\"match\">patient's</span> school"},{"title":"Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies","type":"Proposed Rule","abstract":"This proposed rule would set forth routine updates to the Medicare home health payment rates in accordance with existing statutory and regulatory requirements. In addition, this proposed rule proposes permanent and temporary behavior adjustments and proposes to recalibrate the case-mix weights and update the functional impairment levels; comorbidity subgroups; and low-utilization payment adjustment (LUPA) thresholds for CY 2026. Lastly, this proposed rule proposes policy changes to the face-to-face encounter policy. It also proposes changes to the Home Health Quality Reporting Program (HH QRP) and the expanded Health Value-Based Purchasing (HHVBP) Model requirements. In addition, it would update the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP). Lastly it proposes: a technical change to the HH conditions of participation; updates to DMEPOS supplier conditions of payment; updates to provider and supplier enrollment requirements; and changes to DMEPOS accreditation requirements.","document_number":"2025-12347","html_url":"https://www.federalregister.gov/documents/2025/07/02/2025-12347/medicare-and-medicaid-programs-calendar-year-2026-home-health-prospective-payment-system-hh-pps-rate","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-07-02/pdf/2025-12347.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-12347.pdf?1751314517","publication_date":"2025-07-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"digitally stored and/or transmitted by the <span class=\"match\">patient</span> to the home health agency, that is, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> (G0322). We capture the usage and length of <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> using the start date of the <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> and the number of days of <span class=\"match\">monitoring</span> indicated on the claim. We also looked at the disciplines most often providing <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>. We examined the utilization of telecommunications technology devices during a home health period and <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span> by looking at home health claims that included"},{"title":"Privacy Act of 1974; System of Records","type":"Notice","abstract":"Pursuant to the Privacy Act of 1974, notice is hereby given that VA is modifying the system of records titled \"Patient Medical Records-VA\" (24VA10A7). This system is used for ongoing treatment of individuals and patients; documentation of treatment provided; payment; health care operations such as producing various management and patient follow-up reports; responding to patient and other inquiries; for epidemiological research and other health care related studies; statistical analysis, resource allocation, and planning; providing clinical and administrative support to patient medical care; and determining entitlement and eligibility for VA benefits.","document_number":"2026-13454","html_url":"https://www.federalregister.gov/documents/2026/07/02/2026-13454/privacy-act-of-1974-system-of-records","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-02/pdf/2026-13454.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13454.pdf?1782909925","publication_date":"2026-07-02","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"or Discharge: \n To a third party upon the written request of the <span class=\"match\">patient's</span> next-of-kin in order for a non-judicially declared incompetent <span class=\"match\">patient</span> or, consistent with the best interest of the <span class=\"match\">patient</span>, a member of the <span class=\"match\">patient's</span> family to receive a benefit to which the <span class=\"match\">patient</span> or family member is entitled or to arrange for the <span class=\"match\">patient's</span> discharge from a VA medical facility. Sufficient data to make an informed determination will be made available to such next-of-kin. If the <span class=\"match\">patient's</span> next-of-kin is not reasonably accessible, the Chief of Staff, Director"},{"title":"Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017","type":"Rule","abstract":"The \"Protecting Patient Access to Emergency Medications Act of 2017,\" (the Act) which became law on November 17, 2017, amended the Controlled Substances Act (CSA) to allow for a new registration category for emergency medical services agencies that handle controlled substances. It also established standards for registering emergency medical services agencies, and set forth new requirements for delivery, storage, and recordkeeping related to their handling of controlled substances. In addition, the Act allows emergency medical services professionals to administer controlled substances outside the physical presence of a medical director or authorizing medical professional pursuant to a valid standing or verbal order. The Drug Enforcement Administration is publishing this final rule to conform its regulations to the statutory amendments of the CSA and to otherwise implement its requirements. This final rule adopts, with minor modifications, the notice of proposed rulemaking published on October 5, 2020.","document_number":"2026-02288","html_url":"https://www.federalregister.gov/documents/2026/02/05/2026-02288/registering-emergency-medical-services-agencies-under-the-protecting-patient-access-to-emergency","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-05/pdf/2026-02288.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-02288.pdf?1770153307","publication_date":"2026-02-05","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"director or authorizing medical professional in response to a request by the EMS professional with respect to a specific <span class=\"match\">patient</span>, either in the case of a mass casualty incident, or to ensure the proper care and treatment of a specific <span class=\"match\">patient</span>. \n IV. Regulatory Analyses \n As explained above, DEA is issuing this final rule to amend its regulations in order to make them consistent with the changes made to the CSA by the “Protecting <span class=\"match\">Patient</span> Access to Emergency Medications Act of 2017,” and to otherwise implement the Act's requirements. DEA conducted an analysis"},{"title":"Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Optimizing Virtual Care Grant Program Performance Measures, OMB No. 0906-0075-NEW","type":"Notice","abstract":"In compliance with of the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.","document_number":"2023-02544","html_url":"https://www.federalregister.gov/documents/2023/02/07/2023-02544/agency-information-collection-activities-submission-to-omb-for-review-and-approval-public-comment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-02-07/pdf/2023-02544.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-02544.pdf?1675691127","publication_date":"2023-02-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Resources and Services Administration","name":"Health Resources and Services Administration","id":222,"url":"https://www.federalregister.gov/agencies/health-resources-and-services-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/222","parent_id":221,"slug":"health-resources-and-services-administration"}],"excerpts":"C. 254b(d)(1)(E). Under the Optimizing Virtual Care (OVC) grant program, 29 high-performing health centers received 2-year supplemental awards to increase health care access and quality for underserved populations through virtual care such as telehealth, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, digital <span class=\"match\">patient</span> tools, and health information technology platforms. Specifically, award recipients will use OVC funding to develop and implement innovative evidence-based strategies with the potential to be adapted, leveraged, and scaled across the Health Center Program"},{"title":"Privacy Act of 1974; System of Records","type":"Notice","abstract":"Pursuant to the Privacy Act of 1974, notice is hereby given that VA is modifying the system of records titled, \"National Patient Databases-VA\" (121VA10). VA provides health care services to many Veterans through VHA. During the course of providing health care, VHA collects medical and health information about Veterans under their care. This system is used for planning, distribution, and utilization of resources; monitoring the performance of VHA programs and Veteran population health; and statistical analysis of clinical and administrative support provided within VHA.","document_number":"2025-15587","html_url":"https://www.federalregister.gov/documents/2025/08/15/2025-15587/privacy-act-of-1974-system-of-records","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-15/pdf/2025-15587.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-15587.pdf?1755175532","publication_date":"2025-08-15","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"track and evaluate the ordering and delivery of equipment, services, and <span class=\"match\">patient</span> care; for the planning, distribution, and utilization of resources; to <span class=\"match\">monitor</span> the performance of VISNs and/or outside VA as relevant; to allocate clinical and administrative support to <span class=\"match\">patient</span> medical care; to study, <span class=\"match\">monitor</span>, and report epidemiological trends and disease incidence; for VA's extensive research programs in accordance with VA policy; to assist in workload allocation for <span class=\"match\">patient</span> treatment services including provider panel management, nursing care, clinic"},{"title":"Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program","type":"Rule","abstract":"This final rule contains provisions to improve implementation of the Patient Protection and Affordable Care Act, including payment parameters and provisions related to the HHS-operated risk adjustment and risk adjustment data validation (HHS-RADV) programs, as well as 2027 user fee rates for issuers offering qualified health plans (QHPs) through Federally-facilitated Exchanges (FFEs) and State-based Exchanges on the Federal platform (SBE-FPs). This final rule also includes provisions related to civil money penalties (CMPs) for noncompliant issuers and other responsible entities; standards governing agents, brokers, and web-brokers; the expansion and codification of hardship exemption eligibility; implementation of the State Exchange Improper Payment Measurement (SEIPM); provider access standards and essential community provider standards for QHP certification; QHP certification of non-network plans; a prohibition on issuers from including routine non-pediatric dental services as an Essential Health Benefit (EHB); requirements related to defrayal for the cost of any State-required benefits in addition to the EHB; cost- sharing flexibilities for catastrophic and individual market bronze plans; establishment of catastrophic plans with plan terms of up to 10 consecutive plan years; QHP issuer quality improvement strategies (QISs); and revisions affecting which enrollees are included in Federal Basic Health Program (BHP) payment calculations to States. This final rule also includes amendments to implement certain provisions of the Working Families Tax Cut (WFTC) legislation.","document_number":"2026-10050","html_url":"https://www.federalregister.gov/documents/2026/05/20/2026-10050/patient-protection-and-affordable-care-act-hhs-notice-of-benefit-and-payment-parameters-for-2027-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-20/pdf/2026-10050.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10050.pdf?1779135308","publication_date":"2026-05-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"},{"raw_name":"Office of the Secretary"}],"excerpts":"collect more premiums or submit <span class=\"match\">patients</span> to higher cost sharing on the front end as a way to “entice” participants to remain in the plan for its duration do not align with the inherent purpose of these statutory limits to protect <span class=\"match\">patients</span> from untenable out-of-pocket costs in a given plan year and should not be allowed. However, this same commenter stated that, regarding mid-plan changes for multiple-year plans, if term changes would benefit the <span class=\"match\">patient</span>, such as reduced deductibles or cost sharing to entice a <span class=\"match\">patient</span> to remain enrolled in a particular"},{"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter","type":"Rule","abstract":"The Drug Enforcement Administration and the Department of Health and Human Services are amending their regulations to expand the circumstances under which practitioners registered by the Drug Enforcement Administration are authorized to prescribe schedule III-V controlled substances approved by the Food and Drug Administration for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only telemedicine encounter. Under these new regulations, after a practitioner reviews the patient's prescription drug monitoring program data for the state in which the patient is located during the telemedicine encounter, the practitioner may prescribe an initial six-month supply of such medications (split amongst several prescriptions totaling six calendar months) through audio-only means. Additional prescriptions can be issued under other forms of telemedicine as authorized under the Controlled Substances Act, or after an in-person medical evaluation is conducted. This regulation also requires the pharmacist to verify the identity of the patient prior to filling a prescription. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in- person medical evaluation prior to issuance of a controlled substance prescription. However, this regulation falls under one of the exceptions found within the Ryan Haight Act. Additionally, this regulation does not affect practitioner-patient relationships in cases where an in-person medical evaluation has previously occurred. The purpose of this regulation is to prevent lapses of care by continuing some of the telemedicine flexibilities that currently exist for those patients seeking treatment for opioid use disorder.","document_number":"2025-01049","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01049.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01049.pdf?1736948756","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"practitioner to better determine the state of the <span class=\"match\">patient</span> and ensure the <span class=\"match\">patient</span> is not under the influence of any other substances.\n \n \n Response: \n DEA and HHS agree that an in-person medical evaluation provides a prescribing practitioner with valuable information about the <span class=\"match\">patient</span> that might not be fully discerned via a telemedicine encounter. The in-person medical evaluation allows a prescribing practitioner to conduct a thorough physical assessment of the <span class=\"match\">patient</span>, more accurately assess the <span class=\"match\">patient's</span> physical and mental health, and provides more"},{"title":"Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Optimizing Virtual Care Grant Program Performance Measures","type":"Notice","abstract":"In compliance with of the Paperwork Reduction Act of 1995, HRSA has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30 day comment period for this notice has closed.","document_number":"2022-22868","html_url":"https://www.federalregister.gov/documents/2022/10/21/2022-22868/agency-information-collection-activities-submission-to-omb-for-review-and-approval-public-comment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-10-21/pdf/2022-22868.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-22868.pdf?1666269926","publication_date":"2022-10-21","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Resources and Services Administration","name":"Health Resources and Services Administration","id":222,"url":"https://www.federalregister.gov/agencies/health-resources-and-services-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/222","parent_id":221,"slug":"health-resources-and-services-administration"}],"excerpts":"C. 254b(d)(1)(E). Under the Optimizing Virtual Care (OVC) grant program, 29 high-performing health centers received 2-year supplemental awards to increase health care access and quality for underserved populations through virtual care such as telehealth, <span class=\"match\">remote</span> <span class=\"match\">patient</span> <span class=\"match\">monitoring</span>, digital <span class=\"match\">patient</span> tools, and health information technology platforms. Specifically, award recipients will use OVC funding to develop and implement innovative evidence-based strategies with the potential to be adapted, leveraged, and scaled across the Health Center Program"}]}